The Biotech Analyst Helping Immuno-Oncology Investors Make Better Decisions
Through her research, Mara Goldstein is helping bring capital to companies develop novel products and technologies for treating cancer. She is the former Managing Director, Biotechnology Analyst at Mizuho Securities, providing research coverage of oncology-focused companies.
How does your work advance IO?
I provide equity research on a variety of companies that are developing novel technologies and drugs to treat disease, with a focus in oncology. While I do not make direct investments, I am able to see the direct impact of investments in advancing medical science and drug development.
Through the work that I do, investors are better able to make decisions that bring capital to companies that develop novel products and technologies for the treatment of cancer. If development-stage companies are fully funded, then greater progress and discovery could occur
"Through the work that I do, investors are better able to make decisions that bring capital to companies that develop novel products and technologies for the treatment of cancer."
What are the specific modalities or pathways that you’re keeping an eye on?
Cellular therapies, novel checkpoints, myeloid cell modulators.
What is one prediction you have for immuno-oncology in 2024?
I would predict greater advancement of immune-oncology therapeutics to earlier-stage disease
What makes you passionate about your work?
The ability to marry my interests in science and healthcare with business.
What is your career advice, especially for young women who are entering science careers?
It is okay to not know exactly where you are going but don't be afraid to look at other paths.
What did a mentor do that had an impact on your career?
I had a mentor, Christina Valauri, who taught me how to advocate for myself in a world often filled with men who were older and taller than me.
This Other Eden by Paul Harding
In this article